The clinical effect of mosapride citrate on gastric motility disorders form of functional dyspepsia

Objective To investigate the clinical effect and safety of mosapride citrate on gastric motility disorders form of functional dyspepsia. Methods Fifty-two patients with gastric motility disorders form of functional dyspepsia were randomly divided into 2 groups. Mosapride citrate(5mg three times daily for 4 weeks) was given to 26 patients in the treatment group. cisapride(5mg three times daily for 4 weeks) to 26 patients in the control group.Dyspepsia symptoms were evaluated before treatment and later 4 weeks after treatment. The clinical and adverse reactions were compared between 2 groups.Results After 4 weeks treatment symptoms of both groups including abdominal distention.early satiety. anorexia. belching. nausea or vomiting in patients with gastric motility disorders form of functional dyspepsia had been improved. and symptoms scores were significantly decreased (P0.01). The scores of the symptoms of treatment group before and after the treatment were 8.20±1.69 and 1.68±1.41 respectively (P0.01). the total effective rates were 92.31%. The scores of the symptoms of control group before and after the treatment were 8.10±1.71 and 1.81±1.13 respectively(P0.01).the total effective rates were 88.46%.There were no significant differences in the total effective rates and symptoms scores before treatment and later 4 weeks after treatment between 2 groups (P0.05). No serious adverse reactions were found in 2 groups.Conclusion Mosapride citrate is an effective and safe drug in the treatment of gastric motility disorders form of functional dyspepsia.